Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effects of LLX-424 in Patients With a History of Kidney Stones

NCT06932146 is registered in ClinicalTrials.gov with Lilac Therapeutics, Inc. as lead sponsor.

NCT NCT06932146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06932146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effects of LLX-424 in Patients With a History of Kidney Stones
Lead sponsor
Lilac Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2025
Completion date
September 30, 2025
Enrollment
51 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

kidney stones